Serum resistin in acute myocardial infarction patients with and without diabetes mellitus

Postgraduate Medical Journal

Volumn 87, Issue 1029, 2011, Pages 463-467

  Korah, Tarek E ^a   Ibrahim, Hesham H ^a   Badr, Eman A E ^a   Elshafie, Maathir K ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATINE KINASE; CREATINE KINASE MB; GLUCOSE; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL; TROPONIN I;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, LDL; CREATINE KINASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RESISTIN; TROPONIN I;

EID: 79959639339     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2010.113571     Document Type: Article

References (35)

1. Hu WL, Qiao SB, Hou Q, et al. Plasma resistin is increased in patients with unstable angina. Chin Med J 2007;120:871-5.
2. Yang RZ, Huang Q, Xu A, et al. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003;310:927-35.
3. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-95.
4. Burnett MS, Lee CW, Kinnaird TD, et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005;182:241-8.
5. On YK, Park HK, Hyon MS, et al. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007;71:868-73.
6. JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
7. Iqbal N, Seshadri P, Stern L, et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 2005;9:161-5.
8. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 2005;109:243-56.
9. Stejskala D, Adamovskáa S, Bartekc J, et al. Resistin: concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147:63-9.
10. Thygesen K, Alpert JS, White HD, et al; On behalf of the Joint ESC/ACCF/AHA/ WHF. Task Force for the redefinition of myocardial infarction. Eur Heart J 2007;28:2525-38.
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl 1):S62-7.
12. Bonora E, Tazgher G, Alberich M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000;23:57-63.
13. Bernstein LH, Qamar A, McPherson C, et al. Diagnosis of myocardial infarction: integration of serum markers and clinical descriptors using information theory. Yale J Biol Med 1999;72:5-13.
14. Herrera DJ, Morris K, Johnston C, et al. Automated assay for plasma D-lactate by enzymatic spectrophotometric analysis with sample blank correction. Ann Clin Biochem 2008;45:177-83.
15. Tanno K, Okamura T, Ohsawa M, et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin Chim Acta 2010;411:1774-80.
16. Boder GS, Porter S, Landt Y, et al. Development of monoclonal antibodied for an assay of cardiac troponin-I and preliminarily results in suspected cases of myocardial infarction. Clin Chem 1992;38:2200-14.
17. Judzewitsch R, Pfeifer MA, Best JD, et al. Chronic chlorpropamide therapy of noninsulin-depandant diabetes augments and stimulated insulin secretion by increasing its sensitivity to glucose. J Clin Endocrinol Metab 1982;55:321-8.
18. Kim KH, Lee K, Moon YS, et al. A cysteine-rich adipose tissue- specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001;276:11252-6.
19. Qiao XZ, Yang Y, Xu Z, et al. Relationship between resistin level in serum and acute coronsry syndrome or stable angina pectoris. J Zheijang Univ Sci B 2007;8:875-80.
20. Chu S, Ding W, Li K, et al. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008;72:1249-53.
21. Reilly MP, Lehrke M, Wolfe ML, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9.
22. Vozaroya de Courten B, Degawa YM, Considine RV, et al. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004;53:1279-84.
23. Kaser S, Kaser A, Sandhofer A, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003;309:286-90.
24. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006;70:146-57.
25. Macín SM, Perna ER, Coronel ML, et al. Influence of admission glucose level on long-term prognosis in patients with acute coronary syndrome. Rev Esp Cardiol 2006;59:1268-75.
26. GS. Cardiac troponin I: a highly specific biochemical marker for myocardial infarction. J Clin Immunoassay 1994;17:40-4.
27. Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Circulation 2002;106:202-7.
28. Hellermann JP, Jacobsen SJ, Gersh BJ, et al. Heart failure after myocardial infarction: a review. Am J Med 2002;113:324-30.
29. Utzschneider KM, Carr DB, Tong J, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005;48:2330-3.
30. Al-Daghri N, Chetty R, McTernan PG, et al. Serum resistin is associated with C-reactive protein and LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 2005;4:10-15.
31. de Luis DA, Sagrado MG, Conde R, et al. Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naïve diabetes obese patients. Diabetes Res Clin Pract 2010;89:110-14.
32. Silha JV, Krsek M, Skrha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlation with insulin resistance. Eur J Endocrinol 2003;149:331-5.
33. Helmersson J, Vessby B, Larsson A, et al. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004;109:1729-34.
34. Gustavsson CG, Agardh CD. Markers of inflammation in patients with coronary artery disease are also associated with glycosylated haemoglobin A1c within the normal range. Eur Heart J 2004;25:2120-4.
35. Taegtmeyer H, McNulty P, Young M. Adaptation and maladaptation of the heart in diabetes: Part I. General concepts. Circulation 2002;105: 1727-33.s